H.C. Wainwright maintains Buy rating on Neumora stock ahead of obesity drug data
PositiveFinancial Markets

H.C. Wainwright has reaffirmed its Buy rating on Neumora's stock as anticipation builds for upcoming data on its obesity drug. This is significant because positive results could boost investor confidence and potentially lead to increased market share in the growing obesity treatment sector.
— Curated by the World Pulse Now AI Editorial System








